Literature DB >> 15673502

Alternative treatments for Clostridium difficile disease: what really works?

Lynne V McFarland1.   

Abstract

Vancomycin and metronidazole have been used for treating Clostridium difficile-associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673502     DOI: 10.1099/jmm.0.45753-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  41 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

3.  Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses.

Authors:  Sandra C Numan; Peter Veldkamp; Ed J Kuijper; Renate J van den Berg; Jaap T van Dissel
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

4.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

Authors:  Jason G S Ho; Antonio Greco; Maja Rupnik; Kenneth K-S Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

5.  Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Authors:  Farah Babakhani; Abraham Gomez; Nikki Robert; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

6.  Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review.

Authors:  Phuc Le; Van T Nghiem; Patricia Dolan Mullen; Abhishek Deshpande
Journal:  Infect Control Hosp Epidemiol       Date:  2018-02-21       Impact factor: 3.254

7.  High mobility group box1 protein is involved in acute inflammation induced by Clostridium difficile toxin A.

Authors:  Ji Liu; Bei-Lei Zhang; Chun-Li Sun; Jun Wang; Shan Li; Ju-Fang Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-05-04       Impact factor: 3.848

8.  Trends in Clostridium difficile Disease: Epidemiology and Intervention.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Med       Date:  2009

9.  Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin.

Authors:  George Tannous; Guy Neff; Nyingi Kemmer
Journal:  Case Rep Gastroenterol       Date:  2010-09-28

10.  Probiotics and gastrointestinal disease: successes, problems and future prospects.

Authors:  Eamonn P Culligan; Colin Hill; Roy D Sleator
Journal:  Gut Pathog       Date:  2009-11-23       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.